RxDoctor Payments Data

Bruce Silverman, DO

Neurology · Farmington Hills, MINPI 1356349062

Payments from drug & device makers

$59,956in general payments, 2019–2025

Across 602 payments — averaging $99.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$18K
  • E.r. Squibb & Sons, L.L.C.$15K
  • AbbVie$11K
  • Biogen$7K
  • Novartis$2K
  • EMD Serono, Inc.$1K
  • plus $7K from 50 others

What the payments were for

  • Speaking & faculty fees$16,09258%
  • Travel & lodging$1,2625%
  • Food & beverage$10,46438%
  • Education$270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,956 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$271,601
Medicare patients
522
Services billed
3,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab17$146,245
BetaseronInterferon Beta-1b12$113,440
CopaxoneGlatiramer Acetate12$69,984
Glatiramer Acetate20$32,427
QuliptaAtogepant16$22,759
KeppraLevetiracetam15$22,600
UbrelvyUbrogepant21$21,576
Memantine Hcl ErMemantine Hcl291$18,564
Rasagiline Mesylate74$14,352
Dimethyl Fumarate27$13,140
TrileptalOxcarbazepine22$10,091
Tegretol XrCarbamazepine26$9,541
Carbidopa-LevodopaCarbidopa/Levodopa176$4,329
Donepezil Hcl302$4,112
Levetiracetam144$4,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$500$69,98412 claims
AbbVieQulipta, Ubrelvy$10,780$44,33637 claims
PfizerDilantin$290$1,18112 claims
Upsher-smith Laboratories LLCTopiramate$19$38939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.

Other neurology in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →